The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
High-Dose Ursodeoxycholic Acid Is Associated With the Development of Colorectal Neoplasia in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis
Open accessAbstract
OBJECTIVES: Some studies have suggested that ursodeoxycholic acid (UDCA) may have a chemopreventive effect on the development of colorectal neoplasia in patients with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC). We examined the effects of high-dose (28-30 mg/kg/day) UDCA on the development of colorectal neoplasia in patients with UC and PSC. METHODS: Patients with UC and PSC enrolled in a prior, multicenter randomized placebo-controlled trial of high-dose UDCA were evaluated for the development of colorectal neoplasia. Patients with UC and PSC who received UDCA were compared with those who received placebo. We reviewed the pathology and colonoscopy reports for the development of low-grade or high-grade dysplasia or colorectal cancer. RESULTS: Fifty-six subjects were followed for a total of 235 patient years. Baseline characteristics (including duration of PSC and UC, medications, patient age, family history of colorectal cancer, and smoking status) were similar for both the groups. Patients who received high-dose UDCA had a significantly higher risk of developing colorectal neoplasia (dysplasia and cancer) during the study compared with those who received placebo (hazard ratio: 4.44, 95% confidence interval: 1.30-20.10, P=0.02). CONCLUSIONS: Long-term use of high-dose UDCA is associated with an increased risk of colorectal neoplasia in patients with UC and PSC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kornbluth, A., & Sachar, D. B. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,023
Riddell, R. H., Goldman, H., Ransohoff, D. F., Appelman, H. D., Fenoglio, C. M., Haggitt, R. C., hren, C., Correa, P., Hamilton, S. R., Morson, B. C., et al. (1983) · Human Pathology · doi:10.1016/s0046-8177(83)80175-0 · Cited by 1,862
Diagnosis and Management of Primary Sclerosing Cholangitis
Chapman, R., Fevery, J., Kalloo, A., Nagorney, D. M., Boberg, K. M., Shneider, B., & Gores, G. J. (2010) · Hepatology · doi:10.1002/hep.23294 · Cited by 1,224
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
Lindor, K. D., Kowdley, K. V., Luketic, V. A. C., Harrison, E. M., McCashland, T., Befeler, A. S., Harnois, D., Jorgensen, R., Petz, J., Keach, J., et al. (2009) · Hepatology · doi:10.1002/hep.23082 · Cited by 720
Self-citationBile acids as carcinogens in human gastrointestinal cancers
Bernstein, H., Bernstein, C., Payne, C. M., Dvorakova, K., & Garewal, H. (2005) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2004.08.001 · Cited by 611
Ursodiol for Primary Sclerosing Cholangitis
Lindor, K. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703063361003 · Cited by 598
Self-citationPardi, D. S., Loftus, E. V., Kremers, W. K., Keach, J., & Lindor, K. D. (2003) · Gastroenterology · doi:10.1053/gast.2003.50156 · Cited by 562
Self-citationFarraye, F. A., Odze, R. D., Eaden, J., & Itzkowitz, S. H. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.037 · Cited by 532
Tung, B. Y., Emond, M. J., Haggitt, R. C., Bronner, M. P., Kimmey, M. B., Kowdley, K. V., & Brentnall, T. A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00008 · Cited by 469
Self-citationRubin, P. H., Friedman, S., Harpaz, N., Goldstein, E., Weiser, J., Schiller, J., Waye, J. D., & Present, D. H. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70279-9 · Cited by 355
Cited by
Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management
Shah, S. C., & Itzkowitz, S. H. (2022) · Gastroenterology · doi:10.1053/j.gastro.2021.10.035 · Cited by 838
Primary sclerosing cholangitis
Hirschfield, G. M., Karlsen, T. H., Lindor, K. D., & Adams, D. H. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60096-3 · Cited by 592
Self-citationInteraction of gut microbiota with bile acid metabolism and its influence on disease states
Staley, C., Weingarden, A. R., Khoruts, A., & Sadowsky, M. J. (2017) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-8006-6 · Cited by 581
S-adenosylmethionine in Liver Health, Injury, and Cancer
Lu, S. C., & Mato, J. M. (2012) · Physiological Reviews · doi:10.1152/physrev.00047.2011 · Cited by 554
ACG clinical guideline: primary sclerosing cholangitis
Lindor, K. D., Kowdley, K. V., & Harrison, E. M. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.112 · Cited by 524
Self-citation
Metadata
- Authors
- Eaton, J. E., Silveira, M. G., Pardi, D. S., Sinakos, E., Kowdley, K. V., Luketic, V. A. C., Harrison, E. M., McCashland, T., Befeler, A. S., Harnois, D., Jorgensen, R., Petz, J., & Lindor, K. D.
- Venue
- American Journal of Gastroenterology
- Published
- 2011-09
- Volume
- 106
- Issue
- 9
- Pages
- 1638-1645
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W1983054413
- Cited by
- 268
- References
- 39
- FWCI
- 18.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-Dose Ursodeoxycholic Acid Is Associated With the Development of Colorectal Neoplasia in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis. https://app.cochat.ai/papers/10.1038/ajg.2011.156
- The paper
- Eaton, J. E., Silveira, M. G., Pardi, D. S., Sinakos, E., Kowdley, K. V., Luketic, V. A. C., Harrison, E. M., McCashland, T., Befeler, A. S., Harnois, D., Jorgensen, R., Petz, J., & Lindor, K. D. (2011). High-Dose Ursodeoxycholic Acid Is Associated With the Development of Colorectal Neoplasia in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis. American Journal of Gastroenterology. https://doi.org/10.1038/ajg.2011.156
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.